{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "BHVN",
  "name": "Biohaven Ltd.",
  "url": "https://frontierpicks.com/dossiers/BHVN/",
  "json_url": "https://frontierpicks.com/dossiers/BHVN.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Binary-catalyst biotech: the re-rate off the $7.48 Nov-CRL low stalled at ~$16 in early July and drifted to $13.85 on 2026-08-21. The undated 2H-26 RISE3 topline now races a live $350.0M J.P. Morgan ATM (424B5, 2026-05-04) against ~$270.5M cash at 2026-06-30; targets span $10 (H.C. Wainwright) to $23 (RBC).",
  "invalidation_trigger": "A weekly close below $12 breaks the June consolidation floor and ends the leg off the $7.48 low; secondary break conditions are disclosed ATM issuance under the 2026-05-04 $350.0M program at prices beneath the recent range, or 2H 2026 elapsing without the RISE3 topline.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "binary-catalyst-biotech",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Clinical-stage: no approved revenue driver since the November-2025 VYGLXIA (troriluzole) CRL, so every quarter is a reported loss by construction.",
    "The value-driving RISE3 topline is guided to 2H 2026 with no announced date and can print on any trading day without pre-warning.",
    "A $350.0M at-the-market program with J.P. Morgan has been authorised since the 2026-05-04 prospectus supplement; sales under it need no contemporaneous announcement.",
    "Cash, equivalents, marketable securities and restricted cash were ~$270.5M at 2026-06-30 vs $351.8M at 2026-03-31; the Q2 release carried no runway statement.",
    "Covering-desk dispersion is unusually wide: $10 (H.C. Wainwright) and $11 (BofA) against $19 (Morgan Stanley) and $23 (RBC).",
    "Short interest was ~24.87M shares, about 16.5% of float, at the mid-June 2026 settlement — that figure predates the Q2 print."
  ],
  "body_markdown": "\n> Refresh of coverage first published 2026-06-16; last updated 2026-08-15. Reference close $13.85 (2026-08-21).\n\n## BHVN — Biohaven Ltd.\n\n## Current Thesis\n\nThe leg on offer has not changed shape since the last update, but the clock inside it has moved. Biohaven de-rated from an $18.11 52-week high to $7.48 after the November-2025 Complete Response Letter on VYGLXIA (troriluzole) in spinocerebellar ataxia, then re-rated on the 2026-05-26 opakalim (BHV-7000, selective Kv7.2/7.3 activator) open-label epilepsy disclosure — 54% of patients on 75mg once-daily reaching a ≥50% seizure reduction over six consecutive months, dizziness 5%, fatigue 4%. That re-rating stopped extending in early July near $16. Price eased from $14.64 on 2026-08-14 to $13.85 on 2026-08-21, 23.5% under the 52-week high, with a three-month price change of +46.6% and RSI(14) at 54.7.\n\nWhat is new since the last note is the financing mechanism, now visible rather than hypothetical. A 424B5 prospectus supplement filed 2026-05-04 established a $350.0 million at-the-market program with J.P. Morgan Securities as sales agent under Amendment No. 2 to the Equity Distribution Agreement, rolling in approximately $118.7 million of capacity left unsold under the August-2024 supplement after roughly $181.3 million had already been sold under it. Against approximately $270.5 million of cash, equivalents, marketable securities and restricted cash at 2026-06-30 (from $351.8 million at 2026-03-31) and a Q2 net loss of $137.3 million, the company can issue into any strength without a separate announcement. The RISE3 focal-epilepsy topline remains guided to 2H 2026 with no announced date. The buyer of this equity is buying an undated registrational readout while a pre-authorised share tap sits open beside it.\n\n**The narrative is maturing.** The discovery leg is dated and behind — 2026-05-26 data, the run to ~$16 by early July, the 2026-06-29 BofA downgrade to Underperform. Since 2026-08-12 the news feed has been empty of company releases and price has drifted lower inside its range. The newest sell-side flow is maintenance, not initiation: RBC $23 (2026-08-11), Morgan Stanley $19 (2026-08-12), H.C. Wainwright holding Neutral at $10 with a cut to its FY2030 EPS estimate as reported 2026-08-21. Not saturated — a $10-to-$23 spread across covering desks is not a consensus, and no retail-sentiment clustering shows in the feed.\n\n## Bull Case\n\n- **The registrational readout is intact and reaffirmed.** RISE3 enrolment completed 2026-06-30; the 2026-08-10 Q2 release reiterated topline for 2H 2026. Randomisation is 1:1:1 to opakalim 75mg, 50mg or placebo as adjunctive therapy over an eight-week double-blind period.\n- **Burn is coming down in the reported line, not the narrative.** Q2 2026 R&D of $100.8 million against $184.4 million a year earlier, attributed by the company to strategic reprioritisation; net loss $137.3 million versus $198.1 million in Q2 2025.\n- **The pipeline carries more than one 2026 shot.** Taldefgrobep alfa obesity Phase 2 enrolment complete with topline guided 2H 2026; BHV-1400 IgA-nephropathy pivotal initiation targeted 2H 2026 on Phase 1b showing >60% Gd-IgA1 reduction within 48 hours; BHV-1300 dosed its first Graves' Phase 3 patient 2026-06-29 after Phase 1b >80% mean reductions in pathogenic TSHR-IgG1.\n- **Oncology optionality has a partner attached.** The 2026-07-20 clinical-supply agreement with Regeneron pairs BHV-1530 (FGFR3-directed ADC) with cemiplimab; first Phase 1 data is slated for the ESMO Congress in October 2026.\n- **Two of the three most recent target actions sit above the tape.** RBC $23 and Morgan Stanley $19 both exceed the 2026-08-21 close of $13.85.\n\n## Bear Case\n\n- **The ATM is live and pre-cleared.** With $350.0 million of authorised capacity dated 2026-05-04 and roughly $270.5 million of liquidity at 2026-06-30 against a first-half net loss of $267.8 million, shares can be sold into the market at prevailing prices with no advance signal to holders.\n- **Adjusted EPS missed.** Q2 adjusted EPS of $(0.78) against a $(0.73) consensus on 2026-08-10; GAAP loss per share $(0.91).\n- **The low end of the sell-side book got reinforced, not abandoned.** BofA's Underperform and $11 target from 2026-06-29 rests on opakalim struggling to differentiate against entrenched epilepsy therapies; H.C.\n- **The efficacy anchor is an open-label extension.** The 54%/six-month responder figure came from self-selected completers; RISE3 is an eight-week placebo-controlled comparison, where a high placebo response compresses the delta.\n- **No approved revenue driver exists.** Since the November-2025 troriluzole CRL, every quarter is a loss by construction and each additional pivotal — Graves' Phase 3 running, IgAN pivotal targeted — adds spend before it adds value.\n\n## Setup & Price Structure\n\nThe de-rate reversal built its base between the $7.48 low and the early-July high near $16. Since mid-July the tape has worked a narrower shelf: $14.21 on 2026-07-24, $14.64 on 2026-08-14, $13.85 on 2026-08-21. RSI(14) at 54.7 is mid-scale — no momentum extreme in either direction, and no thrust since the July high. The structure that matters is the June consolidation floor; a weekly close under $12 removes it and puts the whole leg off $7.48 back in play.\n\nPositioning observables, stated as observables: short interest was approximately 24.87 million shares, around 16.5% of float, at the mid-June 2026 settlement — the most recent figure available here, and old enough that it predates the Q2 print. Analyst dispersion runs $10 (H.C. Wainwright) and $11 (BofA) against $19 (Morgan Stanley) and $23 (RBC). There is no scheduled earnings date inside the next 30 days; Q3 results are estimated around 2026-11-09. The issuance channel is authorised and open. The event that resolves the equity has no date attached to it, which means no pre-positioning window exists and gap risk runs in both directions on any trading morning.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2H 2026 (undated)** — BHV-1400 IgA-nephropathy pivotal study initiation.\n- **~2026-10 (est.)** — BHV-1530 Phase 1 data at the ESMO Congress 2026.\n- **~2026-11-09 (est.)** — Q3 2026 results; first refresh of the cash line after $270.5 million at 2026-06-30.\n\n## Elapsed catalysts\n\n- **~2H 2026 (undated, company guidance)** — RISE3 Phase 2/3 focal-epilepsy topline for opakalim. Reaffirmed 2026-08-10 with no scheduled date; it can print inside this window or well after it. *(passed 16d ago)*\n- **~2H 2026 (undated)** — Taldefgrobep alfa Phase 2 obesity topline; enrolment complete as of the 2026-08-10 release. *(passed 16d ago)*\n- **Any trading day** — ATM sales under the 2026-05-04 $350.0 million program require no contemporaneous announcement; the first confirmation would come in a periodic filing. *(passed 114d ago)*\n\n## What Would Change Our Mind\n\nThe break that matters first is structural: losing the June consolidation floor that has held every pullback since the 2026-05-26 re-rating. Concretely, a weekly close below $12 ends the leg off the $7.48 low and says the market has stopped paying for the RISE3 option ahead of data.\n\nThree non-price conditions would change the read independently. First, disclosed ATM issuance at prices beneath the recent range — visible in a periodic filing or a share count materially above the level implied by the Q2 per-share loss — resets the denominator before the data resolves anything. Second, a RISE3 topline where the 75mg arm misses statistical significance on seizure-frequency reduction, or lands at a responder rate inside the 40–50% band typical of approved adjunctive anti-seizure medicines, validates the BofA and H.C. Wainwright case directly. Third, 2H 2026 passing without the topline, or company language reframing it into 2027, converts the binary into another financing quarter with nothing resolved.\n\nOn the other side, a RISE3 win with clean nervous-system tolerability, or a non-dilutive inflow — partnership, milestone, regional licence — that removes the financing question ahead of data, would upgrade the setup materially from where the evidence stands now.\n\n## Correlation Notes\n\n- Idiosyncratic risk dominates. On topline day, index and sector beta are close to irrelevant; the distribution is set by one placebo-controlled comparison.\n- Between now and then the name trades as a high-beta, pre-revenue biotech: sensitive to XBI-style risk appetite and to rate expectations, because all of the value sits in cash flows that do not exist yet.\n- Read-across risk runs through any other late-stage Kv7 activator in focal epilepsy. A rival pivotal that reports first sets the differentiation bar the BofA thesis is built on.\n- The 2026-07-20 Regeneron clinical-supply agreement ties part of the oncology optionality to a partner's willingness to keep supplying cemiplimab; that leg is not independent of Regeneron's own priorities.\n- With short interest last observed near 16.5% of float (mid-June 2026 settlement), the flow response to any binary is mechanically amplified in whichever direction the data points.",
  "first_seen": "2026-06-16",
  "last_analyzed": "2026-08-23T12:18:53+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}